Retinoblastoma: A Sixteen-Year Review of the Presentation, Treatment, and Outcome from a Tertiary Care Institute in Northern India
Ocular Oncology and Pathology · 2018 · 4 (1) · 23-32
DOI: 10.1159/000477408 ↗Kurz gefasst
Fachartikel in der Zeitschrift Ocular Oncology and Pathology, online erschienen am 05.07.2017. Verfasst von Usha Singh und 5 weiteren Autor:innen. Beteiligte Einrichtung: Advanced Eye Centre, Department of Ophthalmology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Purpose
To study epidemiology, demographic profile, clinical characteristics, and outcome in pediatric patients with retinoblastoma.
Methods
This was a retrospective review of retinoblastoma patients of a tertiary institute from January 1st 1998 to December 31st 2014.
Results
The study included 467 patients (618 eyes) with a mean age of 34.7 ± 24.6 months (median = 30; 15 days to 144 months). Retinoblastoma was bilateral in 151 (32.3%) and there were 61.7% males. Intraocular disease was seen in 301 patients (451 eyes [72.9%]) and extraocular in 166 patients (167 eyes; 27.0%). Out of the 347 (74.3%) who received treatment, primary treatment was chemoreduction in 228 (65.7%) and enucleation in 117 (33.7%), while 25.6% of patients refused treatment and 151 (43.5%) defaulted therapy. Local recurrence was seen in 20 (4.3%), metastasis in 2 (0.4%), and deaths in 13 (2.8%) (average follow-up 28.5 ± 44.4 months). Histopathological high risk features were significantly less in the eyes that received chemoreduction (5.0%) versus primary enucleation (20.8%) (p < 0.0004), but there was no difference in the rate of metastasis, recurrence, and death between the two.
Conclusions
The majority of retinoblastoma patients in our study had advanced disease, and nearly a third had extraocular extension. There were a significant number of therapy refusals and dropouts. Chemoreduction led to a significant decrease in the histopathological risk factors without affecting the outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Advanced Eye Centre, Department of Ophthalmology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
- Department of Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
- Department of Radiotherapy, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Zitieren
APA
Singh, U., Katoch, D., Kaur, S., Dogra, M. R., Bansal, D., & Kapoor, R. (2018). Retinoblastoma: A Sixteen-Year Review of the Presentation, Treatment, and Outcome from a Tertiary Care Institute in Northern India. Ocular Oncology and Pathology, 4(1), 23-32. https://doi.org/10.1159/000477408
Vancouver
Singh U, Katoch D, Kaur S, Dogra MR, Bansal D, Kapoor R. Retinoblastoma: A Sixteen-Year Review of the Presentation, Treatment, and Outcome from a Tertiary Care Institute in Northern India. Ocular Oncology and Pathology. 2018;4(1):23-32. doi:10.1159/000477408
BibTeX
@article{Singh2018,
author = {Singh, Usha and Katoch, Deeksha and Kaur, Savleen and Dogra, Mangat Ram and Bansal, Deepak and Kapoor, Rakesh},
title = {Retinoblastoma: A Sixteen-Year Review of the Presentation, Treatment, and Outcome from a Tertiary Care Institute in Northern India},
journal = {Ocular Oncology and Pathology},
year = {2018},
volume = {4},
number = {1},
pages = {23--32},
doi = {10.1159/000477408}
}
EUVIMED